Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon.
2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Expert Opin Pharmacother. 2021 Sep;22(13):1685-1728. doi: 10.1080/14656566.2021.1925647. Epub 2021 Jun 2.
Prostate cancer is one of the most common neoplasms in men. For many years the mainstay of treatment was androgen deprivation therapy, but during last decade many novel agents have emerged, accompanied by increased costs for healthcare systems.
In this literature review, the authors provide a pharmacoeconomic review of several pharmaceutical agents used in several disease stages, by summarizing evidence from cost-analysis, cost-effectiveness, cost-utility, cost-saving, cost-benefit and budgetary impact analysis studies.
The rapid development of therapeutic agents for prostate cancer has put a great budgetary burden on healthcare systems, since these drugs are prolonging survival and improving quality of life . Since existing data are now mature enough from a number of clinical trials with long-term follow-up, policy makers should propose not only the most clinically effective but also the most cost-effective agents, in order for every patient to gain access at least to some of these therapies. Docetaxel addition seems to be a cost-effective option, when compared to both abiraterone and enzalutamide (due to costs related to acquisition and side effects). Cabazitaxel is a strong candidate after docetaxel failure, while both denosumab and bisphosphonates are cost-effective for reducing skeletal-related events in metastatic disease.
前列腺癌是男性最常见的肿瘤之一。多年来，雄激素剥夺疗法一直是治疗的主要手段，但在过去十年中，出现了许多新型药物，同时也增加了医疗保健系统的成本。
在这篇文献综述中，作者通过总结成本分析、成本效益、成本效用、成本节约、成本效益和预算影响分析研究中的证据，对几种用于不同疾病阶段的药物进行了药物经济学评价。
治疗前列腺癌的治疗药物的快速发展给医疗保健系统带来了巨大的预算负担，因为这些药物延长了生存时间并提高了生活质量。由于目前有许多具有长期随访的临床试验数据已经足够成熟，政策制定者不仅应该提出最具临床疗效的药物，还应该提出最具成本效益的药物，以便让每个患者至少能获得其中一些治疗方法。与阿比特龙和恩杂鲁胺相比，多西他赛联合治疗似乎是一种具有成本效益的选择（由于与获得和副作用相关的成本）。在多西他赛治疗失败后，卡巴他赛是一种强有力的候选药物，而地舒单抗和双膦酸盐在治疗转移性疾病中的骨骼相关事件方面都具有成本效益。
